source
- Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trialGerman biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
- Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competitionMarrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…